Austin, Texas – October 19, 2026 -- Mortgage rates climbed 74 basis points in just over a month, from 6.66% in late August to 7.40% on October 8, cutting purchasing power by 7.2% for a buyer with a $2,000 monthly principal-and-interest budget, according to the Realtor.com Market Clock report.

San Diego – October 19, 2026 -- The Vistage CEO Confidence Index fell 3.4 points to 80.8 in Q3 2026 from 84.2 in the prior quarter, marking the third consecutive quarterly decline in small and midsize business (SMB) CEO sentiment.

Expectations for the year ahead dropped the most. Only 19% of CEOs expect the U.S. economy to improve over the next year, down 10 percentage points from last quarter and 13 points below Q3 2025. A further 34% expect conditions to worsen, up 8 points.

New York – October 19, 2026 -- Melio's plans range from $0 to $80 per month, and a new Better Business Advice review names the platform the best bill pay software for small business, citing its centralized accounts payable workflow.

San Jose – October 19, 2026 -- PUFsecurity, a subsidiary of eMemory Technology, has received OCP S.A.F.E. approval for its PUFrt root-of-trust IP after an independent Scope 3 security assessment, and the product is now listed on the OCP Marketplace.

The company presented PUFrt at Microsoft's Caliptra Workshop on October 12, the opening day of the sold-out 2026 OCP Global Summit. The workshop drew nearly 400 attendees. Principal Security Architect Kent Chuang spoke on moving the open-source Caliptra specification into production-ready silicon for AI data centers.

San Diego – October 19, 2026 -- The U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) will meet on July 29, 2026, to review Capricor Therapeutics' Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), less than four weeks before the agency's August 22, 2026 PDUFA target action date.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) disputed the post-hoc analyses in the FDA's briefing materials, two days before an advisory committee meets on July 29 to discuss its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) said The Lancet has published results from its Phase 3 HOPE-3 trial, in which Deramiocel slowed upper limb function decline by 54 percent versus placebo in Duchenne muscular dystrophy (PUL 2.0, p=0.03).

The randomized, double-blind, placebo-controlled trial enrolled 106 participants and met its primary endpoint. Capricor also reports a clinically meaningful cardiac benefit. The results rest on the company's prespecified Statistical Analysis Plan version 3.0 (SAP 3.0).

SAN DIEGO – October 19, 2026 -- The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3, with no abstentions, that available evidence did not support the effectiveness of Capricor Therapeutics' Deramiocel for cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), leaving the company's PDUFA target action date of August 22, 2026 as the next decision point.

Vancouver – October 19, 2026 -- Nevada Organic Phosphate Inc. (CSE: NOP) reported that drill hole MM26-11 intersected 28.7 metres (94.2 feet) of the target Meade Peak Member in northeast Nevada, extending the confirmed strike length of phosphate mineralization to more than 3.3 kilometres.

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) ended the second quarter with about $237.9 million in cash, cash equivalents and marketable securities, down from about $318.1 million at Dec. 31, 2025. The decline came as an FDA advisory committee voted 9 against and 3 in favor on whether evidence shows Deramiocel is effective for cardiomyopathy in Duchenne muscular dystrophy (DMD) patients.